TickerFacts.

Compare

NeoGenomics Inc vs UL Solutions Inc. vs 20/20 Biolabs, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearNeoGenomics Inc
NEO		UL Solutions Inc.
ULS		20/20 Biolabs, Inc.
AIDX
Year ended2025-12-312025-12-312025-12-31
Revenue$727.33M$3.05B$2.05M
Revenue growth (YoY)+10.1%+6.4%+16.7%
Gross margin43.2%49.5% (computed)29.6%
Operating margin-15.9%17.1%-162.9%
Net margin-14.9%10.6%-182.8%
Net income-$108.03M$325.00M-$3.74M
EPS (Diluted)n/a$1.60-$0.76
Operating cash flow$5.23M$600.00M-$1.92M
Free cash flow-$21.78M$403.00Mn/a
Cash & equivalents$159.62M$295.00M$1.03M
Total assets$1.36B$2.92B$4.14M
Total liabilities$523.27M$1.63B$4.16M
Shareholders' equity$836.56M$1.29B-$19.2K
Return on year-end equity-12.9%25.1%n/a
Shares outstanding128.15M201.03M5.44M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearNeoGenomics IncUL Solutions Inc.20/20 Biolabs, Inc.
Latest$727.33M
Ended 2025-12-31		$3.05B
Ended 2025-12-31		$2.05M
Ended 2025-12-31
1 year earlier$660.57M
Ended 2024-12-31		$2.87B
Ended 2024-12-31		$1.75M
Ended 2024-12-31
2 years earlier$591.64M
Ended 2023-12-31		$2.68B
Ended 2023-12-31		n/a
3 years earlier$509.73M
Ended 2022-12-31		$2.52B
Ended 2022-12-31		n/a
4 years earlier$484.33M
Ended 2021-12-31		n/an/a